menu
    • menu
    [{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Advanced Accelerator Applications","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Advanced Accelerator Applications \/ Endocyte ","highestDevelopmentStatusID":"10","companyTruncated":"Advanced Accelerator Applications \/ Endocyte "},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"ABX Advanced Biochemical Compounds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Approved","graph3":"Advanced Accelerator Applications","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Advanced Accelerator Applications \/ Endocyte Inc","highestDevelopmentStatusID":"12","companyTruncated":"Advanced Accelerator Applications \/ Endocyte Inc"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"PSMA","graph1":"Oncology","graph2":"Approved","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Advanced Accelerator Applications \/ Advanced Accelerator Applications","highestDevelopmentStatusID":"12","companyTruncated":"Advanced Accelerator Applications \/ Advanced Accelerator Applications"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Advanced Accelerator Applications \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advanced Accelerator Applications \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Advanced Accelerator Applications

    Menu

    Advanced Accelerator Applications

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Advanced Accelerator Applications

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Advanced Accelerator Applications

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MHRA Grants Marketing Authorisation for Novartis’ Radioligand Therapy Pluvicto® (Lutetium (¹⁷⁷lu) Vipi...

                            Details : Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) is indicated for the treatment of adult patients with PSMA-positive mCRPC who have been treated with AR pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.

                            Brand Name : Pluvicto

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 11, 2022

                            Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Advanced Accelerator Applications

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Advanced Accelerator Applications

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : ABX Advanced Biochemical Compounds

                            Deal Size : $172.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Otsuka Subsidiary to Receive Payment and Royalties from Approval in U.S. of - Out-licensed by ABX in Germany, ...

                            Details : Advanced Accelerator Applications (AAA) and Endocyte, Inc., both Novartis companies, successfully completed full-scale development of Pluvicto and also received Breakthrough Therapy designation from the U.S. FDA last year.

                            Brand Name : Pluvicto

                            Molecule Type : Large molecule

                            Upfront Cash : $12.0 million

                            March 29, 2022

                            Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : ABX Advanced Biochemical Compounds

                            Deal Size : $172.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Advanced Accelerator Applications

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Advanced Accelerator Applications

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novartis Pluvicto™ Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA-...

                            Details : FDA approval was based on VISION trial, where patients with pre-treated PSMA-positive mCRPC who received Pluvicto plus standard of care had a statistically significant reduction in risk of death1; both alternate primary endpoints of OS and radiographic P...

                            Brand Name : Pluvicto

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 23, 2022

                            Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Advanced Accelerator Applications

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Advanced Accelerator Applications

                            France arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : ITM

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ITM expands PSMA-617 supply agreement for no-carrier-added Lutetium-177

                            Details : ITM will provide Endocyte with supply of n.c.a 177Lu for its investigational 177Lu-PSMA-617 radioligand therapy for patients with metastatic castration-resistant prostate cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 02, 2020

                            Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : ITM

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth